CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 139 enrolled
Drug / intervention
GORE EXCLUDER® Bifurcated Endoprosthesis-Low Permeabilitydevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00593814
NCT00593814Phase 4Completed
CompareCT.gov

A Clinical Evaluation of the GORE EXCLUDER® Bifurcated Endoprosthesis - Low Permeability in the Primary Treatment of Infrarenal Abdominal Aortic Aneurysms

W.L.Gore & Associates·interventional·Posted Jan 15, 2008·Updated Jan 8, 2018

In Brief

A Phase 4 clinical trial evaluating GORE EXCLUDER® Bifurcated Endoprosthesis-Low Permeability for Aortic Aneurysm, Abdominal. Completed, enrolled 139 participants.

Detailed Summary

The purpose of this study is to evaluate the performance of the GORE EXCLUDER® Bifurcated Endoprosthesis-Low Permeability in the primary treatment of infrarenal abdominal aortic aneurysms.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAortic Aneurysm, Abdominal
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 15, 2008
Enrollment StartJun 1, 2005
Primary CompletionFeb 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 18.5 years ago

Interventions

GORE EXCLUDER® Bifurcated Endoprosthesis-Low Permeabilitydevice

Implant